A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

• Status: RECRUITING
• Trial end date: 2026-05-01

Summary

This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.

• Phase: PHASE3

Details

• Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
• Collaborator: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
• Treatments: Docetaxel; Irinotecan; Paclitaxel